FDA approves Merck’s KEYTRUDA® (pembrolizumab) in combination with Inlyta® (axitinib)
Merck announced the FDA has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase inhibitor, for first-line treatment of patients with advanced renal cell carcinoma. The approval is based on findings from the pivotal Phase 3 KEYNOTE-426 trial. April 22, 2019